Everyone Should See This
Man Cured of Cancer Applying Hemp Oil (Real Weed) Cannabis
People are Running from There Only Cure
2009 - causes of death - annual causes of death by
cause)
Cause of death1
Number
All causes
2,436,652
Cardiovascular diseases
779,367
Malignant neoplasms
568,668
Lack of Health Insurance3
44,789
Drug induced2
37,485
Suicide
36,547
Motor vehicle accidents
36,284
Septicemia (infections)
35,587
by Firearms
31,224
Accidental poisoning
30,504
Alcohol induced
23,199
Homicide
16,591
Human immunodeficiency virus (HIV)
9,424
Viral hepatitis
7,652
Cannabis (Marijuana)
0
1 Based on the International Classification of Diseases,
Tenth Revision, Second Edition, 2004
cause)
Cause of death1
Number
All causes
2,436,652
Cardiovascular diseases
779,367
Malignant neoplasms
568,668
Lack of Health Insurance3
44,789
Drug induced2
37,485
Suicide
36,547
Motor vehicle accidents
36,284
Septicemia (infections)
35,587
by Firearms
31,224
Accidental poisoning
30,504
Alcohol induced
23,199
Homicide
16,591
Human immunodeficiency virus (HIV)
9,424
Viral hepatitis
7,652
Cannabis (Marijuana)
0
1 Based on the International Classification of Diseases,
Tenth Revision, Second Edition, 2004
Feds To Grant Exclusive Cannabinoid License To Pharma Firm
The U.S. federal government's Department of Health and Human Services seems
about ready to award exclusive rights to apply marijuana as a medical
therapeutic. You read that correctly: "exclusive rights."
Now, I don't think of myself as a conspiracy theorist. But when the federal
government keeps taking actions that, even when considered separately but
especially when viewed together, all seem to be part of a bigger plan to pave
the way for the pharmaceutical industry to bulldoze the cottage medical
marijuana industry, I start getting antsy.
"We find it hypocritical and incredible that on the one hand, the U.S.
Department of Justice is persecuting cannabis patient associations, asserting
that the federal government regards marijuana as having absolutely no medical
value, despite overwhelming clinical evidence," said Union of Medical Marijuana Patients director
James Shaw. "On the other hand, the Department of Health and Human Services is
planning to grant patent rights with possible worldwide application to develop
medicine based on cannabis."
"Though UMMP welcomes any potential new research that could come from
KannaLife Sciences' federal endorsement, it is highly disconcerting that the
contemplated grant is an exclusive one," the organization posted on its website.
UMMP on Facebook
James Shaw,
Union of Medical Marijuana Patients: "It makes no sense for the government to
provide [the patent], which the government owns, to a single company with
exclusive rights"
"It is a grave injustice that patient association[s] in California are now
facing a coordinated and comprehensive attack by the DOJ, while one
pharmaceutical company in New York stands to profit tremendously from the
monopolization of medical cannabis thanks to the HHS," UMMP posted.
You may recall that Toke of the Town columnist Ron Marczyk pointed
out that the U.S. federal government, a few years back, took out patents on
"cannabinoids as antioxidants and neuroprotectants," even while officially
denying that cannabis has any medical value.
Well, turns out they weren't just holding onto that patent for the fun of
it. The latest piece of the puzzle to fall into place is the announcement last
month in the Federal Register.
After years of inaction, it seems they are "contemplating" the grant of an
exclusive patent license to practice the invention embodied in its U.S. Patent
to a company called KannaLife Sciences, Inc., which has offices in New
York.
According to Shaw, "it makes no sense for the government to provide U.S.
Patent 6,630,507, which the government owns, to a single company with exclusive
rights."
Shaw urged medical marijuana patient associations and patients using
cannabis for medicinal reasons to protest this giveaway to one pharmaceutical
firm.
Celebrity Wonder
Thoma Kikis, founder of KannaLife Sciences, is also a
designer, filmmaker and entrepreneur
Who, exactly, is this "KannaLife Sciences," based at 4 Tradewinds Drive in
Bayville, N.Y.?
Here's their Facebook page, on which they proudly
shared a link to the Federal Register notice, but as yet haven't responded to
this question posted 14 hours ago from a Facebook user: "you guys get exclusive
rights to a USD Gov't patent on medical marijuana as they put CA & CO
dispensaries out of business?!"
Nor to a comment to that post: "If your company is as socially responsible
as you claim to be, you will answer this."
The founder of KannaLife Sciences is one Thoma Kikis,
according to AngelList, who apparently also founded Inventlab and
something called Ovie Entertainment. Kikis, a designer, filmmaker and
entrepreneur, co-produced the film Alps (by Oscar-nominated director
Yorgos Lanthimos), produced Darkon (being remade by Brad Pitt's
Plan B and distributed by IFC), and was executive producer of It's A Disaster
(with Julia Stiles and David Cross).
According to the LinkedIn profile of CEO Dean Petkanas, "KannaLife
Sciences, Inc. is a socially responsible, developmental stage
phyto-medical/bio-pharmaceutical company that specializes in the research,
development, and packaging of pharmacological products derived from botanical
sources, including the cannabis taxa."
KannaLife's plan for generating revenue and growth is intended to come from
(i.) KannaLife's proprietary branding POS and hermetic packaging systems for the
medical marijuana industry; (ii.) KannaLife's branded anti-oxidant and recovery
skin care ointments and creams; and (iii.) the development, marketing and sale
of KannaLife biopharmaceutical and phyto-pharmaceutical products derived from
cannabis for the treatment of patients suffering with neuro-degenerative,
neuro-toxic and oxidative stress related diseases and disorders.
The Company's focus on product development was born from the burgeoning
market in the United States in the use of traditional healthcare models of
treatment, utilizing medicinal marijuana and other APIs found in the genus of
the cannabis taxa.
KannaLife intends to profit from the acquisition, development, marketing
and sale of phyto-medical drugs and products derived from cannabinol ("CBN") and
cannabidiol ("CBD") compounds as art [sic] and parcel to the Company's drug
development plan. The disease indications to which the Company intends to target
for the development of its products are centered on patients suffering from
diseases with neuro-degenerative and/or neuro-toxic profiles.
In addition the Company has developed a unique "blue ocean" approach to
participating in the fast growing multi-billion dollar medical marijuana
industry in establishing a "Gold Standard" in QA for delivering a consistent and
reliable product to the consumer for dispensing medicinal marijuana in
hermetically sealed packaging.
Google+
Dean Petkanas, CEO,
KannaLife
"The prospective exclusive license territory may be worldwide, and the
field of use may be limited to:
"The development and sale of cannabinoid(s) and cannabidiol(s) based
therapeutics as antioxidants and neuroprotectants for use as delivery in humans,
for the treatment of hepatic encephalopathy, as claimed in the
Licensed Patent Rights." [Italics added.]
Hepatic encephalopathy's effects are due to liver impairment or liver
failure, and can range from forgetfulness, confusion and irritability to
inverted sleep-waking patterns, tremor, difficulties with coordination and
trouble writing. More severe cases result in lethargy, somnolence, and
eventually coma. In the intermediate stages, a characteristic jerking of the
limbs -- asterixis -- is observed. There is disorientation and amnesia, and
"uninhibited behavior" may occur.
Coma and seizures are found in the most advanced stages of hepatic
encephalopathy; cerebral edema (brain swelling) leads to death.
Now, does the phrase "for the treatment of hepatic encephalopathy" mean the
license is limited to that one condition, or is this a broader license to cover
more or all medicinal applications of cannabinoids?
A mid-day Friday email from Toke of the Town to KannaLife got a
response from founder Thoma Kikis, who referred me to CEO Dean Petkanas; a
follow-up call to Petkanas hadn't yet been returned by late afternoon.
In the meantime, let's look some more at the language of the Federal
Register notice.
"The technology describes pharmaceutical compositions of cannabinoids that
are useful as tissue protectants, such as neuroprotectants and
cardioprotectants," the notice reads. "The cannabinoids compounds may be used,
for example, in the treatment of acute ischemic neurological insults or chronic
neurodegenerative diseases."
The next paragraph gets really interesting, because it clearly reveals the
anti-scientific and even superstitious way our United States government views
the psychoactive effects of cannabis. (Please note that there is a real
difference between "toxicity" -- which means it's poisonous, and can produce
death -- and "psychoactivity," which can mean, in the case of cannabis, that it
just changes your mental state.)
"Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are particularly
advantageous since they avoid toxicity that is encountered with psychoactive
cannabinoids at high doses," [italics added], the notice reads.
See how they just turned "psychoactivity" into "toxicity," folks?
There you have it, right from the eminently trustworthy United States
Government, that same government which has patented the medical use of natural
compounds occurring in the cannabis plant: THC is toxic.
Of course, it's demonstrably not only nontoxic, but is, as DEA Administrative Law Judge Francis L. Young pointed
out, "one of the safest therapeutically active substances known to man."
Should it really surprise anyone to find the federal government telling an
outright lie when it comes to marijuana?
This is, after all, the same government that has been handing out free
marijuana for 30 years to patients in the Compassionate Investigative New Drug program, even
while claiming cannabis has no medical value and thus classifying it as a
Schedule I narcotic.
According to the notice in the Federal Register, public comments will be
accepted through Monday, December 19.
Comments need to be submitted in writing by Monday, Dec. 19,
to:
Betty B. Tong, Ph.D.
Senior Licensing and Patenting Manager
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Telephone (301) 594-6565 (note that NIH will only accept written
comments for consideration)
Fax (301) 402-0220
Website http://www.ott.nih.gov/contactus/licensing_and_patenting.aspx
Email [email protected]
Tags: cannabinoids, exclusive rights, patent license
More links from around the web!
Glad you liked it. Would you like to share?
Facebook
Twitter
Sharing this page …
Thanks! Close
Add New Comment
Optional: Login
below.
about ready to award exclusive rights to apply marijuana as a medical
therapeutic. You read that correctly: "exclusive rights."
Now, I don't think of myself as a conspiracy theorist. But when the federal
government keeps taking actions that, even when considered separately but
especially when viewed together, all seem to be part of a bigger plan to pave
the way for the pharmaceutical industry to bulldoze the cottage medical
marijuana industry, I start getting antsy.
"We find it hypocritical and incredible that on the one hand, the U.S.
Department of Justice is persecuting cannabis patient associations, asserting
that the federal government regards marijuana as having absolutely no medical
value, despite overwhelming clinical evidence," said Union of Medical Marijuana Patients director
James Shaw. "On the other hand, the Department of Health and Human Services is
planning to grant patent rights with possible worldwide application to develop
medicine based on cannabis."
"Though UMMP welcomes any potential new research that could come from
KannaLife Sciences' federal endorsement, it is highly disconcerting that the
contemplated grant is an exclusive one," the organization posted on its website.
UMMP on Facebook
James Shaw,
Union of Medical Marijuana Patients: "It makes no sense for the government to
provide [the patent], which the government owns, to a single company with
exclusive rights"
"It is a grave injustice that patient association[s] in California are now
facing a coordinated and comprehensive attack by the DOJ, while one
pharmaceutical company in New York stands to profit tremendously from the
monopolization of medical cannabis thanks to the HHS," UMMP posted.
You may recall that Toke of the Town columnist Ron Marczyk pointed
out that the U.S. federal government, a few years back, took out patents on
"cannabinoids as antioxidants and neuroprotectants," even while officially
denying that cannabis has any medical value.
Well, turns out they weren't just holding onto that patent for the fun of
it. The latest piece of the puzzle to fall into place is the announcement last
month in the Federal Register.
After years of inaction, it seems they are "contemplating" the grant of an
exclusive patent license to practice the invention embodied in its U.S. Patent
to a company called KannaLife Sciences, Inc., which has offices in New
York.
According to Shaw, "it makes no sense for the government to provide U.S.
Patent 6,630,507, which the government owns, to a single company with exclusive
rights."
Shaw urged medical marijuana patient associations and patients using
cannabis for medicinal reasons to protest this giveaway to one pharmaceutical
firm.
Celebrity Wonder
Thoma Kikis, founder of KannaLife Sciences, is also a
designer, filmmaker and entrepreneur
Who, exactly, is this "KannaLife Sciences," based at 4 Tradewinds Drive in
Bayville, N.Y.?
Here's their Facebook page, on which they proudly
shared a link to the Federal Register notice, but as yet haven't responded to
this question posted 14 hours ago from a Facebook user: "you guys get exclusive
rights to a USD Gov't patent on medical marijuana as they put CA & CO
dispensaries out of business?!"
Nor to a comment to that post: "If your company is as socially responsible
as you claim to be, you will answer this."
The founder of KannaLife Sciences is one Thoma Kikis,
according to AngelList, who apparently also founded Inventlab and
something called Ovie Entertainment. Kikis, a designer, filmmaker and
entrepreneur, co-produced the film Alps (by Oscar-nominated director
Yorgos Lanthimos), produced Darkon (being remade by Brad Pitt's
Plan B and distributed by IFC), and was executive producer of It's A Disaster
(with Julia Stiles and David Cross).
According to the LinkedIn profile of CEO Dean Petkanas, "KannaLife
Sciences, Inc. is a socially responsible, developmental stage
phyto-medical/bio-pharmaceutical company that specializes in the research,
development, and packaging of pharmacological products derived from botanical
sources, including the cannabis taxa."
KannaLife's plan for generating revenue and growth is intended to come from
(i.) KannaLife's proprietary branding POS and hermetic packaging systems for the
medical marijuana industry; (ii.) KannaLife's branded anti-oxidant and recovery
skin care ointments and creams; and (iii.) the development, marketing and sale
of KannaLife biopharmaceutical and phyto-pharmaceutical products derived from
cannabis for the treatment of patients suffering with neuro-degenerative,
neuro-toxic and oxidative stress related diseases and disorders.
The Company's focus on product development was born from the burgeoning
market in the United States in the use of traditional healthcare models of
treatment, utilizing medicinal marijuana and other APIs found in the genus of
the cannabis taxa.
KannaLife intends to profit from the acquisition, development, marketing
and sale of phyto-medical drugs and products derived from cannabinol ("CBN") and
cannabidiol ("CBD") compounds as art [sic] and parcel to the Company's drug
development plan. The disease indications to which the Company intends to target
for the development of its products are centered on patients suffering from
diseases with neuro-degenerative and/or neuro-toxic profiles.
In addition the Company has developed a unique "blue ocean" approach to
participating in the fast growing multi-billion dollar medical marijuana
industry in establishing a "Gold Standard" in QA for delivering a consistent and
reliable product to the consumer for dispensing medicinal marijuana in
hermetically sealed packaging.
Google+
Dean Petkanas, CEO,
KannaLife
"The prospective exclusive license territory may be worldwide, and the
field of use may be limited to:
"The development and sale of cannabinoid(s) and cannabidiol(s) based
therapeutics as antioxidants and neuroprotectants for use as delivery in humans,
for the treatment of hepatic encephalopathy, as claimed in the
Licensed Patent Rights." [Italics added.]
Hepatic encephalopathy's effects are due to liver impairment or liver
failure, and can range from forgetfulness, confusion and irritability to
inverted sleep-waking patterns, tremor, difficulties with coordination and
trouble writing. More severe cases result in lethargy, somnolence, and
eventually coma. In the intermediate stages, a characteristic jerking of the
limbs -- asterixis -- is observed. There is disorientation and amnesia, and
"uninhibited behavior" may occur.
Coma and seizures are found in the most advanced stages of hepatic
encephalopathy; cerebral edema (brain swelling) leads to death.
Now, does the phrase "for the treatment of hepatic encephalopathy" mean the
license is limited to that one condition, or is this a broader license to cover
more or all medicinal applications of cannabinoids?
A mid-day Friday email from Toke of the Town to KannaLife got a
response from founder Thoma Kikis, who referred me to CEO Dean Petkanas; a
follow-up call to Petkanas hadn't yet been returned by late afternoon.
In the meantime, let's look some more at the language of the Federal
Register notice.
"The technology describes pharmaceutical compositions of cannabinoids that
are useful as tissue protectants, such as neuroprotectants and
cardioprotectants," the notice reads. "The cannabinoids compounds may be used,
for example, in the treatment of acute ischemic neurological insults or chronic
neurodegenerative diseases."
The next paragraph gets really interesting, because it clearly reveals the
anti-scientific and even superstitious way our United States government views
the psychoactive effects of cannabis. (Please note that there is a real
difference between "toxicity" -- which means it's poisonous, and can produce
death -- and "psychoactivity," which can mean, in the case of cannabis, that it
just changes your mental state.)
"Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are particularly
advantageous since they avoid toxicity that is encountered with psychoactive
cannabinoids at high doses," [italics added], the notice reads.
See how they just turned "psychoactivity" into "toxicity," folks?
There you have it, right from the eminently trustworthy United States
Government, that same government which has patented the medical use of natural
compounds occurring in the cannabis plant: THC is toxic.
Of course, it's demonstrably not only nontoxic, but is, as DEA Administrative Law Judge Francis L. Young pointed
out, "one of the safest therapeutically active substances known to man."
Should it really surprise anyone to find the federal government telling an
outright lie when it comes to marijuana?
This is, after all, the same government that has been handing out free
marijuana for 30 years to patients in the Compassionate Investigative New Drug program, even
while claiming cannabis has no medical value and thus classifying it as a
Schedule I narcotic.
According to the notice in the Federal Register, public comments will be
accepted through Monday, December 19.
Comments need to be submitted in writing by Monday, Dec. 19,
to:
Betty B. Tong, Ph.D.
Senior Licensing and Patenting Manager
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Telephone (301) 594-6565 (note that NIH will only accept written
comments for consideration)
Fax (301) 402-0220
Website http://www.ott.nih.gov/contactus/licensing_and_patenting.aspx
Email [email protected]
Tags: cannabinoids, exclusive rights, patent license
More links from around the web!
Glad you liked it. Would you like to share?
Sharing this page …
Thanks! Close
Add New Comment
Optional: Login
below.